UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Eventual success rate and predictors of success for oncology drugs tested in phase I trials

International journal of cancer, 2023-01, Vol.152 (2), p.276-282

2023

Volltextzugriff (PDF)

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020

JAMA internal medicine, 2022-12, Vol.182 (12), p.1319

2022

Volltextzugriff (PDF)

Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers

BMC cancer, 2023-01, Vol.23 (1), p.46-8, Article 46

2023

Volltextzugriff (PDF)

Crossover in Adjuvant Trastuzumab Trials: Sparing Toxicity in Patient Care

American journal of clinical oncology, 2022-10, Vol.45 (10), p.438-441

2022

Volltextzugriff (PDF)

Multiple myeloma: challenges with deciding the optimal sequencing strategy

Frontiers in pharmacology, 2023-07, Vol.14, p.1231720-1231720

2023

Volltextzugriff (PDF)

Scoping Review of Published Oncology Meta-analyses in High-Impact Oncology Journals

JAMA network open, 2023-06, Vol.6 (6), p.e2318877-e2318877

2023

Volltextzugriff (PDF)

Assessing patient burden and benefit: A decade of cabozantinib clinical trials

International journal of cancer, 2024-04, Vol.154 (8), p.1464-1473

2024

Volltextzugriff (PDF)

Eligibility for Human Leukocyte Antigen–Based Therapeutics by Race and Ethnicity

JAMA network open, 2023-10, Vol.6 (10), p.e2338612-e2338612

2023

Volltextzugriff (PDF)

Assessing Patient Risk, Benefit, and Outcomes in Drug Development: Insights From Afatinib Clinical Trials Across Diverse Cancer Indications

Clinical therapeutics, 2024-06, Vol.46 (6), p.e107-e113

2024

Volltextzugriff (PDF)

Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials

Cancer medicine (Malden, MA), 2024-05, Vol.13 (9), p.e7130-n/a

2024

Volltextzugriff (PDF)

The Promise and Pitfalls of Using Crowdsourcing in Research Prioritization for Back Pain: Cross-Sectional Surveys

Journal of medical Internet research, 2017-10, Vol.19 (10), p.e341-e341

2017

Volltextzugriff (PDF)

Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trials

BMJ Oncology, 2024-07, Vol.3 (1), p.e000229

2024

Volltextzugriff (PDF)

Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed

Nature reviews. Clinical oncology, 2023-12, Vol.20 (12), p.885-895

2023

Volltextzugriff (PDF)

A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target

European journal of cancer (1990), 2023-01, Vol.178, p.227-233

2023

Volltextzugriff (PDF)

Systematic Review and Meta-Analysis of Randomized Trials Testing Interventions to Reduce Physician Burnout

The American journal of medicine, 2024-03, Vol.137 (3), p.249-257.e1

2024

Volltextzugriff (PDF)

Cisplatin shortage results in substitution of more expensive treatments: Drug cost analysis

European journal of cancer (1990), 2024-05, Vol.202, p.114019-114019, Article 114019

2024

Volltextzugriff (PDF)

Profile of the Oncology Physician Workforce and the Characteristics of Attrition

JCO oncology practice, 2023-07, Vol.19 (7), p.465-472

2023

Volltextzugriff (PDF)

A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers

Journal of cancer policy, 2022-03, Vol.31, p.100319-100319, Article 100319

2022

Volltextzugriff (PDF)

Characteristics and outcomes of new molecular oncology drug approvals, in combination or monotherapy

Journal of cancer policy, 2024-03, Vol.39, p.100462-100462, Article 100462

2024

Volltextzugriff (PDF)

Cost of Drug Wastage From Dose Modification and Discontinuation of Oral Anticancer Drugs

JAMA oncology, 2023-09, Vol.9 (9), p.1238

2023

Volltextzugriff (PDF)

Frequency and Characteristics of Trials Using Medical Writer Support in High-Impact Oncology Journals

JAMA network open, 2023-02, Vol.6 (2), p.e2254405-e2254405

2023

Volltextzugriff (PDF)

Cancer Drug Price and Novelty in Mechanism of Action

JAMA network open, 2023-12, Vol.6 (12), p.e2347006-e2347006

2023

Volltextzugriff (PDF)

Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review

Targeted oncology, 2024-03, Vol.19 (2), p.161-173

2024

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Humans
(15)
Oncology
(13)
Cross-Sectional Studies
(9)
Neoplasms - Drug Therapy
(7)
Clinical Trials
(6)
Drug Development
(6)
General & Internal Medicine
(6)
Medicine, General & Internal
(6)
Antineoplastic Agents - Therapeutic Use
(5)
Fda Approval
(5)
Tumors
(5)
Cancer Therapies
(4)
Online Only
(4)
Original Investigation
(4)
Patients
(4)
Response Rate
(4)
Response Rates
(4)
Adverse Events
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Eventual success rate and predictors of success for oncology drugs tested in phase I trials

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020

Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers

Crossover in Adjuvant Trastuzumab Trials: Sparing Toxicity in Patient Care

Multiple myeloma: challenges with deciding the optimal sequencing strategy

Scoping Review of Published Oncology Meta-analyses in High-Impact Oncology Journals

Assessing patient burden and benefit: A decade of cabozantinib clinical trials

Eligibility for Human Leukocyte Antigen–Based Therapeutics by Race and Ethnicity

Assessing Patient Risk, Benefit, and Outcomes in Drug Development: Insights From Afatinib Clinical Trials Across Diverse Cancer Indications

Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials

The Promise and Pitfalls of Using Crowdsourcing in Research Prioritization for Back Pain: Cross-Sectional Surveys

Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trials

Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed

A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target

Systematic Review and Meta-Analysis of Randomized Trials Testing Interventions to Reduce Physician Burnout

Cisplatin shortage results in substitution of more expensive treatments: Drug cost analysis

Profile of the Oncology Physician Workforce and the Characteristics of Attrition

A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers

Characteristics and outcomes of new molecular oncology drug approvals, in combination or monotherapy

Cost of Drug Wastage From Dose Modification and Discontinuation of Oral Anticancer Drugs

Frequency and Characteristics of Trials Using Medical Writer Support in High-Impact Oncology Journals

Cancer Drug Price and Novelty in Mechanism of Action

Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review

Suchergebnisse filtern